Adrenomedullin 2 (ADM2)

**Adrenomedullin 2 (ADM2)**, also known as *intermedin*, is a secreted peptide hormone in the calcitonin gene-related peptide (CGRP) superfamily. It is encoded by the ADM2 gene (chromosome 22q13.33) and processed from a larger pre-pro-peptide to generate active forms. ADM2 acts as a multifunctional regulator of cardiovascular and metabolic physiology: it exerts potent vasodilatory effects, protects the myocardium, stabilizes endothelial permeability (notably in hypoxia), and modulates both water/electrolyte homeostasis and energy metabolism. Its biological actions are mediated primarily through binding and activating CRLR or CTR G protein-coupled receptors in complex with RAMPs, leading to cAMP signaling. ADM2 is being studied as a potential therapeutic target in cardiovascular disease, metabolic syndrome, and inflammation, though no targeted drugs have yet reached the market[1][2][3].\n\n**References:** ADM2 is supported as a true and scientifically validated peptide hormone and therapeutic target in published literature and molecular databases[1][2][3].

Other names

IntermedinIntermedin-shortIntermedin-longIMDIMDLIMDSAM2DJ579N16.4FLJ21135protein ADM2

Activates calcitonin receptor-like receptor (CRLR) and calcitonin receptor (CTR) complexes with receptor activity-modifying proteins (RAMP1, RAMP2, RAMP3), leading to cAMP pathway activation and modulation of vascular, metabolic, and immune processes[1][2][3].